What was recalled
The U.S. Food and Drug Administration (FDA) has issued a Class II recall involving a specific pharmaceutical ingredient manufactured by Shoolin Pharma Chem LLP. This is not a finished medication that you would typically pick up at a pharmacy counter for immediate use. Instead, the product in question is Tadalafil USP, a chemical substance listed under its generic name and Universal Product Code (NDC) 85702-001-08. The specific batch identified in this recall is labeled with the lot number TLF2506001, which has an expiration date of May 31, 2028. The physical form of this item is a 1.00 KG bag (equivalent to 1000 grams) of the powder or compound. It is explicitly marked as "Rx only," indicating it requires a prescription for handling in professional settings, and carries the critical designation "For Prescription Compounding Only." This means it is intended to be used by pharmacists or healthcare professionals who mix custom medications for individual patients, rather than being sold directly to consumers as a final product.
The manufacturer, Shoolin Pharma Chem LLP, is located in Gujarat, India, at Block/Survey no 408, B/H Ratnamani Tubes, Near Maruti Inox, Indrad, Kadi, Mahesania, 382715. The company identifies the substance by its Chemical Abstracts Service number, CAS NO 171596-29-5. Despite being manufactured abroad, this specific batch was distributed nationwide across the United States before the recall was announced on August 3, 2026. If you are a healthcare provider or a compounding pharmacy in the U.S., it is essential to check your current inventory against these details. Look for bags containing exactly 1 kilogram of Tadalafil USP with the specific batch number TLF2506001. The nationwide distribution pattern suggests that this product could be anywhere in the country, making verification crucial for any professional who handles bulk pharmaceutical ingredients.
Understanding what was recalled helps clarify why this is a serious matter for those in the supply chain. This is not a consumer-facing recall for a branded pill you might have swallowed; it is a recall of an active pharmaceutical ingredient used to create custom treatments. The classification as a Class II recall indicates that use of or exposure to the violative product may cause temporary, medically reversible adverse health consequences, or where the probability of serious adverse health consequences is remote. However, because this ingredient is foundational to creating other medications, its quality and compliance are paramount. The recall stems from Good Manufacturing Practice (CGMP) deviations noted during an FDA inspection, highlighting that the issue lies in how the product was made or handled, rather than just what the product is. For anyone involved in the compounding process, identifying this exact batch is the first step in ensuring patient safety and regulatory compliance.
The hazard, explained
In this specific instance, the FDA has identified that Shoolin Pharma Chem LLP’s Tadalafil USP product was recalled due to Current Good Manufacturing Practice (CGMP) deviations. To understand why this matters, we first need to look at what CGMP actually means in the pharmaceutical world. These are not just bureaucratic boxes to check; they are rigorous, science-based standards designed to ensure that every single unit of medicine is consistently produced and controlled according to quality standards. When an agency like the FDA notes "CGMP deviations" during an inspection, it signals that the manufacturing process failed to meet these critical safeguards. This isn't necessarily a claim that the drug is currently contaminated with a visible impurity, but rather that the controls meant to prevent contamination, incorrect dosing, or instability were not properly maintained.
Tadalafil belongs to a class of drugs known as phosphodiesterase type 5 (PDE5) inhibitors. It works by relaxing muscles in blood vessels, which increases blood flow to specific areas of the body. Because it affects cardiovascular function, its potency and purity are paramount. In an ideal CGMP-compliant facility, every step—from the raw materials entering the building to the final bagging of the 1-kilogram powder—is monitored for environmental controls, equipment calibration, and personnel hygiene. Deviations can occur in many ways: perhaps the air filtration system failed to keep particulates out, maybe the mixing equipment wasn't calibrated correctly leading to uneven distribution of the active ingredient, or possibly documentation of sterilization processes was incomplete. Any of these failures create a scenario where the final product could be unsafe.
The physical mechanism of harm in CGMP violations often stems from unpredictability. If the compounding environment was not sterile, the Tadalafil powder could harbor microbial contamination, which is dangerous for anyone using it to compound prescriptions. If the mixing process was flawed, one bag might contain a higher concentration of the drug than another. For a medication that must be dosed precisely by a pharmacist or physician, this variability can lead to accidental overdosing or underdosing. Overdose can cause severe drops in blood pressure, dizziness, and heart issues, while underdosing means the patient receives no therapeutic benefit. Furthermore, without proper stability testing controls—which are part of CGMP—the chemical structure of the drug could degrade in ways not accounted for, potentially creating harmful byproducts.
It is important to note that while the FDA has flagged these deviations, the specific nature of the error (such as whether it was a microbial issue or a potency issue) is not detailed in the public recall notice. However, the classification of this recall as Class II indicates that use or exposure to the product might cause temporary or medically reversible health problems, or where the serious threat of illness is remote. Despite this classification, the uncertainty introduced by manufacturing failures means that patients relying on prescriptions compounded from this batch cannot be assured of the drug's safety or efficacy. The deviation undermines the fundamental guarantee that when you take a pharmaceutical ingredient, it is exactly what it says it is, in the exact amount stated.
Who is most at risk
When evaluating the potential impact of this recall, it is important to first understand the specific nature of the product involved. This is not a consumer-ready item sitting on a pharmacy shelf for direct purchase by patients. The recalled product is Tadalafil USP, distributed in 1.00 kg bags, and clearly labeled "For Prescription Compounding Only." This distinction places the primary risk squarely within the professional sphere of healthcare providers, specifically pharmacists who specialize in compounding medications. These are the individuals and facilities that receive this bulk material to create customized dosages for patients who may not be able to take standard commercial pills. Therefore, the immediate circle of exposure is limited to the supply chain: the distributors who shipped these bags nationwide and the compounding pharmacies that received them for processing.
For the general public, the risk is indirect but still significant. If a compounding pharmacy unknowingly used this specific batch (TLF2506001) of Tadalafil to prepare medication for a patient, that patient becomes part of the affected group. Tadalafil is commonly prescribed to treat erectile dysfunction and pulmonary arterial hypertension. Patients relying on these compounded formulations often do so because they require precise dosages or specific inactive ingredients that commercial manufacturers do not provide. For these individuals, the integrity of their medication is critical. While the recall classification is Class II, indicating that use or exposure to the product might cause temporary health problems or pose slight threat of serious nature, the uncertainty surrounding CGMP (Current Good Manufacturing Practice) deviations means we cannot guarantee the purity, strength, or quality of the drug contained within those bags.
Certain groups may be particularly vulnerable to the consequences of receiving substandard medication. Elderly patients, who are a primary demographic for treating erectile dysfunction and pulmonary hypertension, often manage multiple chronic conditions simultaneously. They may be taking other medications that interact with Tadalafil, such as nitrates for heart conditions. If the compounded drug lacks potency or contains impurities due to manufacturing deviations, it could lead to unpredictable therapeutic effects. This unpredictability is dangerous for anyone with underlying cardiovascular issues. Furthermore, patients who have waited weeks for their specialized compounded prescription may face emotional and physical distress if they suddenly find themselves without their necessary treatment during a recall investigation.
It is also worth noting that while the product was distributed nationwide in the USA, the risk is not uniform across all regions. It depends entirely on which specific compounding pharmacies received inventory from Shoolin Pharma Chem LLP for this particular batch. There is no public list of affected patients provided in the recall facts, so individuals cannot know for certain if they are at risk without contacting their pharmacy directly. This lack of targeted notification means that the burden of verification falls heavily on the patient to proactively check with their healthcare provider, rather than relying on a direct alert from the manufacturer or distributor.
How to tell if you have the recalled item
Because this recall involves a raw pharmaceutical ingredient rather than a finished consumer product sitting on a pharmacy shelf, identifying the affected stock requires careful attention to specific labeling details and documentation. If you are a healthcare professional, compounding pharmacy, or distributor handling bulk materials, you must verify your inventory against the precise identifiers listed in the FDA’s notice. The process begins with locating the physical packaging or the accompanying Certificate of Analysis (CoA) for the material you currently hold.
First, look closely at the brand name and manufacturer information. The recalled product is explicitly labeled under the brand Shoolin Pharma Chem. You need to confirm that the supplier is Shoolin Pharma Chem LLP. Be aware that this company is located in India, specifically at Block/Survey no 408, B/H Ratnamani Tubes, Near Maruti Inox, Indrad, Kadi, Mahesania, Gujarat, 382715. If your documentation lists a different manufacturer or a different address for Shoolin Pharma, this specific recall lot does not apply to you.
Next, examine the product description and quantity. The recall applies specifically to TADALAFIL USP. This is a prescription-only substance intended "For Prescription Compounding Only." You must verify that the bag contains exactly 1.00 KG (which is 1,000 grams) of the compound. If you have smaller vials, different weights, or non-USP grade materials, they are not part of this specific recall action. The packaging should clearly state "Rx only" and include the warning "For Prescription Compounding Only."
The most critical step is matching the batch and identification numbers. You must find the following unique identifiers on your records or the container label:
- NDC Number: 85702-001-08
- CAS Number: 171596-29-5
- Batch/Lot Number: TLF2506001
- Date of Expiry: May 31, 2028
If your stock matches all of the above criteria—specifically the NDC 85702-001-08 and Batch TLF2506001—you have the recalled item. It is important to note that this product was distributed nationwide across the United States. Therefore, even if you purchased it from a domestic distributor or a local pharmaceutical supplier, it may still be part of this recall if the upstream manufacturer and batch details match. Do not rely solely on where you bought it; the manufacturing origin in Gujarat, India, is the key link. If any detail does not match exactly, your product is likely safe and unrelated to this specific CGMP deviation issue.
What to do — step by step
If you are involved with the distribution or compounding of pharmaceuticals, receiving this specific batch of Tadalafil USP from Shoolin Pharma Chem LLP requires immediate and careful attention. Because the FDA has classified this recall as a Class II event, it indicates a situation where temporary or medically reversible health consequences could occur, though serious adverse outcomes are less likely than in Class I scenarios. However, the underlying issue—Current Good Manufacturing Practice (CGMP) deviations noted during an FDA inspection—means the integrity of the product cannot be guaranteed. Therefore, your primary obligation is to halt all commercial activities involving this material right away.
First, stop using and distributing the recalled inventory immediately. This applies whether you are a pharmacy compounding specialist, a distributor, or a healthcare provider holding stock. The product in question is identified as Tadalafil USP, 1.00 KG (1KG/1000gm)-bag, intended for prescription compounding only. It carries NDC 85702-001-08 and Batch Number TLF2506001, with an expiration date of May 31, 2028. Do not attempt to verify the quality of this specific batch yourself by testing it; the CGMP deviations identified by federal inspectors suggest systemic process failures that cannot be remedied by simple spot-checking. Quarantine any remaining units in a secure area to prevent accidental use or further distribution.
Second, contact the responsible party for instructions on disposition. In many official recalls, the agency provides a clear remedy such as a refund, repair, or replacement. However, in this specific instance, the recall details do not state a specific remedy. This absence of a stated remedy is significant and requires proactive communication. You must reach out to Shoolin Pharma Chem LLP directly at their address in Indrad, Kadi, Mahesania, Gujarat, India, or through their official distribution channels in the United States to determine how they intend to handle the return or destruction of these goods. Do not assume that because a remedy is not publicly listed that you are not entitled to compensation or guidance; it simply means you must initiate that dialogue yourself.
Third, document everything thoroughly. Keep records of when you received the notice, the quantity of the affected batch (TLF2506001), and all correspondence with the manufacturer or distributor. If you have already dispensed any compound made from this bulk drug substance to patients, you may need to consult with regulatory experts or legal counsel regarding notification procedures, although the facts provided do not specify patient notification requirements. Finally, ensure that any returned materials are handled according to federal hazardous waste and pharmaceutical disposal regulations to maintain compliance while the situation is resolved.
Your refund, repair, or replacement options
When you encounter a product recall, the most pressing question is often, "What do I get in return?" In this specific instance involving Shoolin Pharma Chem LLP’s batch of Tadalafil USP, the official FDA recall notice presents a unique and somewhat unusual scenario regarding remediation. The record explicitly states that the remedy is "not stated." This absence of a declared remedy can feel unsettling or confusing, but it is important to understand what this means in the context of pharmaceutical compounding recalls versus consumer goods.
Unlike a recalled toaster or a car seat, where the manufacturer typically provides a clear path for a refund, repair, or replacement part, drug recalls—particularly those involving bulk ingredients for prescription compounding—operate differently. The primary goal of this recall is not to exchange a defective item for a new one, but to remove a potentially non-compliant product from the supply chain entirely. Because the hazard cited is "CGMP Deviations" (Current Good Manufacturing Practice) noted during an FDA inspection, the issue relates to the manufacturing environment and quality control processes rather than a single, easily replaceable defect in the chemical itself. Therefore, there is no standard "replacement bag" available because the entire production batch is under scrutiny for potential systemic quality issues.
Since specific contact details for returns or refunds are not provided in the current recall documentation, your immediate course of action should focus on containment and professional consultation rather than attempting to process a return yourself. If you are a pharmacy or compounding facility that received this product, do not attempt to sell, use, or distribute it. Instead, you must rely on the distribution records associated with your purchase. The recall was distributed nationwide in the USA, which means the responsibility for tracking down recipients falls heavily on the entities that handled the logistics of the shipment.
If you are a consumer who received a compound made from this bulk ingredient, do not try to return the raw material to Shoolin Pharma Chem LLP directly, as they likely deal in bulk industrial quantities rather than individual consumer returns. Your path forward is through your healthcare provider or the pharmacy that dispensed the medication. They have the professional obligation to verify if their source inventory included this specific lot number (TLF2506001) and NDC (85702-001-08). If they confirm the exposure, they will coordinate with their supplier to ensure you are not harmed and may adjust your prescription or provide alternative sourcing from a compliant manufacturer.
In summary, while there is no explicit refund or replacement mechanism listed in this notice, the "remedy" here is the cessation of use. The system relies on the pharmaceutical supply chain’s internal protocols to handle the logistics of removal. If you have questions about your specific situation, your best option is to contact the pharmacy that dispensed your medication or consult your healthcare provider for guidance on alternative treatments, rather than waiting for a direct response from the manufacturer regarding financial restitution.
What can happen if you ignore it
When a pharmaceutical product is recalled due to Current Good Manufacturing Practice (CGMP) deviations, the primary concern is not always an immediate, visible defect, but rather a fundamental breach of the safety protocols designed to protect your health. In this specific case involving Tadalafil USP from Shoolin Pharma Chem LLP, the FDA identified that the manufacturing process did not meet established quality standards during inspection. It is crucial to understand what "CGMP deviations" actually means for you as a consumer. These are not minor administrative errors; they are failures in the rigorous controls required to ensure that every single tablet or powder batch is pure, potent, and free from harmful contaminants.
If you continue to use this product despite the recall, you are exposing yourself to unpredictable risks that cannot be quantified by a simple symptom chart. Because the manufacturing environment or processes were found to be non-compliant, there is no guarantee that the Tadalafil in these bags is chemically identical to the standard specification. This uncertainty can manifest in several dangerous ways. First, the potency of the drug may vary significantly from batch to batch. You might receive a dose that is too weak to be effective, leading to treatment failure and potentially dangerous health outcomes if you are relying on this medication for a serious condition. Conversely, and perhaps more critically, the concentration could be higher than labeled. Taking an unexpectedly high dose of Tadalafil can lead to severe hypotension (dangerously low blood pressure), priapism (a prolonged and painful erection that can cause permanent tissue damage), cardiovascular strain, and other systemic side effects that require emergency medical intervention.
Furthermore, CGMP deviations often raise the specter of contamination. The manufacturing controls that were found lacking are specifically designed to prevent cross-contamination from other substances, bacterial growth, or foreign particulate matter. By ignoring the recall, you bypass the safety net that ensures the drug is sterile and pure. You might be ingesting impurities that your body is not equipped to handle, leading to allergic reactions, toxicity, or long-term health complications that are difficult to diagnose because the source of the illness is obscured by the irregular nature of the contaminated product.
There is also a significant regulatory and legal dimension to ignoring this recall. The FDA has classified this as a Class II recall, indicating that use of the product could cause temporary or medically reversible adverse health consequences. However, "reversible" does not mean "harmless." If you suffer an injury from using a non-compliant drug, proving causation and seeking compensation becomes exponentially more difficult if you ignored the official advisory. You are essentially assuming all liability for any adverse event. The remedy here is straightforward: do not gamble with your physiological response to a medication that has been flagged as potentially unreliable. The uncertainty introduced by CGMP failures creates a risk profile that is entirely unnecessary and entirely avoidable by simply returning the product.
Staying safe: broader tips
When dealing with pharmaceutical products, particularly those intended for professional compounding rather than direct-over-the-counter consumer use, the foundation of safety lies in rigorous verification and supply chain diligence. Because this recall involves an ingredient specifically labeled "For Prescription Compounding Only," it is crucial to understand that these materials are not finished medications but raw components used by licensed pharmacists to create customized treatments. For patients who rely on compounded therapies, your primary defense is open communication with your healthcare provider and pharmacist. Always ensure that the pharmacy you visit adheres to strict Good Manufacturing Practices (GMP) and maintains transparent sourcing protocols. If a medication looks different than usual in color, texture, or packaging, do not hesitate to pause and verify its origin. Compounding pharmacies are required to source their active pharmaceutical ingredients from reputable manufacturers who comply with federal standards; asking about the supplier of the raw materials is a standard and reasonable question that demonstrates your engagement in your own care.
For the broader public and healthcare professionals alike, staying informed about drug recalls requires proactive habits rather than passive waiting. The FDA issues numerous alerts regularly, many of which are routine quality control measures that prevent potential issues before they reach patients. To stay ahead of such developments, consider subscribing to the FDA’s official email notification service for drug safety communications. This ensures you receive timely updates directly from the source, allowing you or your provider to act quickly if a specific product batch is identified as non-compliant with Current Good Manufacturing Practices (CGMP). CGMP deviations, while not always indicative of immediate harm, signal that quality control processes may have been compromised, which can affect the purity, strength, or consistency of the medication. Understanding this distinction helps remove unnecessary alarm while maintaining appropriate vigilance.
Additionally, proper storage and handling of any prescription medication, whether compounded or commercially manufactured, play a significant role in maintaining its integrity until it is dispensed. While manufacturers ensure stability during production, environmental factors such as excessive heat, humidity, or light can degrade active ingredients over time. Ensure that your home medicine cabinet is cool, dry, and out of direct sunlight. For those who manage multiple prescriptions, consider using pill organizers with clear labeling to prevent mix-ups, especially when different suppliers provide visually similar tablets or capsules. Regularly reviewing the expiration dates on all medications in your household can also help you identify products that may need to be disposed of safely through local take-back programs, thereby preventing accidental use of outdated or compromised drugs. By combining these general safety habits with the specific information provided in this recall notice, you empower yourself and your healthcare team to make informed decisions about your treatment plan.